SARS-CoV-2 and the resulting disease, COVID-19, caused economic and global health crises. Vaccination is the main strategy to reduce its spread. However, with the emergence of new variants, new therapeutic strategies are urgently required. Thus, in this project, we aim to develop a novel class of neutralizing antibodies for the treatment and prevention of SARS-CoV-2 infection.